Skip to content

Maravai LifeSciences

US · MRVI #3116 by market cap Listed 2020
6.98 -0.21 -2.92%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Maravai LifeSciences

Maravai Lifesciences Holdings, Inc. engages in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm’s brands include TriLink BioTechnologies, Cygnus, Glen Research, and Alphazyme. It operates through the TriLink and Cygnus segments. The TriLink segment manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The Cygnus segment sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. It also operates through the following geographical segments: North America, Asia Pacific, Europe, the Middle East, and Africa, and Latin and Central America. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Founded
2014
CEO
Mr. Bernd Brust
Employees
435
Headquarters
San Diego, California, United States of America
Fiscal year end
12-31
Website
maravai.com

Company profile

Exchange
US
Symbol
MRVI
Market-cap rank
#3116
Listing date
2020-11-20
Market cap
1.04B
Float cap
716.18M
Shares out
149.25M
Float shares
102.60M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Maravai LifeSciences discussion 0 comments

Add a comment